Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Neth J Med ; 77(7): 268, 2019 09.
Article in English | MEDLINE | ID: mdl-31582584
2.
Aging Clin Exp Res ; 30(7): 839-843, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29032522

ABSTRACT

BACKGROUND AND AIMS: To examine antimicrobial resistance of commonly isolated pathogens in elderly hospitalized patients. METHODS: Data regarding all clinically significant isolates from blood and urine cultures of patients admitted to a multilevel geriatric hospital during March 2015 to April 2016 were collected. Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standard Institute guidelines. RESULTS: Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae were the most common isolates, with proportions of extended spectrum beta-lactamase positivity of 60, 40, and 61% respectively. Adjusted logistic regression models indicated that resistance of Escherichia coli to ceftriaxone [odds ratio (OR) 2.8, 95% confidence interval (CI) 1.5-5.1], ceftazidime (OR 2.8, 95% CI 1.5-5.1), ciprofloxacin (OR 2.2, 95% CI 1.2-4.0), amoxicillin/clavulanic acid (OR 2.3, 95% CI 1.2-4.3), and trimethoprim/sulfamethoxazole (OR 2.4, 95% CI 1.4-4.3) was significantly higher in skilled nursing wards than in acute geriatric wards. Resistance of Proteus mirabilis to ceftriaxone (OR 3.1, 95% CI 1.5-6.4) and Klebsiella pneumoniae to ciprofloxacin (OR 3.2, 95% CI 1.3-7.9) was significantly higher in skilled nursing wards than in acute wards. CONCLUSIONS AND DISCUSSION: Antimicrobial resistance was found to be high in a multilevel geriatric hospital, especially in skilled nursing wards. These findings call for rethinking of the empirical antimicrobial therapy and of the efforts for prevention of nosocomial infection.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Bacterial/physiology , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , Proteus mirabilis/drug effects , Aged , Anti-Bacterial Agents/pharmacology , Cross Infection/prevention & control , Escherichia coli/isolation & purification , Female , Geriatrics , Hospitals, Special , Humans , Klebsiella pneumoniae/isolation & purification , Male , Proteus mirabilis/isolation & purification , Retrospective Studies , beta-Lactamases/blood , beta-Lactamases/urine
3.
Neoplasma ; 60(3): 262-73, 2013.
Article in English | MEDLINE | ID: mdl-23373995

ABSTRACT

Rhodamine-6G is a fluorescent dye binding to mitochondria, thus reducing the intact mitochondria number and inhibiting mitochondrial metabolic activity. Resultantly, the respiratory chain functioning becomes blocked, the cell "suffocated" and eventually destroyed. Unlike normal cells, malignant cells demonstrate a priori reduced mitochondrial numbers and aberrant metabolism. Therefore, a turning point might exist, when Rhodamine-induced loss of active mitochondria would selectively destroy malignant, but spare normal cells. Various malignant vs. non-malignant cell lines were cultured with Rhodamine-6G at different concentrations. In addition, C57Bl mice were implanted with B16-F10 melanoma and treated with Rhodamine-6G at different dosage/time regimens. Viability and proliferation of cultured tumor cells were time and dose-dependently inhibited, up to 90%, by Rhodamine-6G, with profound histological signs of cell death. By contrast, inhibition of normal control cell proliferation hardly exceeded 15-17%. Melanoma-transplanted mice receiving Rhodamine-6G demonstrated prolonged survival, improved clinical parameters, inhibited tumor growth and metastases count, compared to their untreated counterparts. Twice-a-week 10-6M Rhodamine-6G regimen yielded the most prominent results. We conclude that malignant, but not normal, cells are selectively destroyed by low doses of Rhodamine-6G. In vivo, such treatment selectively suppresses tumor progression and dissemination, thus improving prognosis. We suggest that selective anti-tumor properties of Rhodamine-6G are based on unique physiologic differences in energy metabolism between malignant and normal cells. If found clinically relevant, low concentrations of Rhodamine-6G might be useful for replacing, or backing up, more aggressive nonselective chemotherapeutic compounds.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Proliferation/drug effects , Melanoma/pathology , Rhodamines/pharmacology , Animals , Disease Progression , Dose-Response Relationship, Drug , Energy Metabolism , Humans , Male , Melanoma/drug therapy , Melanoma/mortality , Mice , Mice, Inbred C57BL , Neoplasm Metastasis , Survival Rate , Tumor Cells, Cultured
4.
Int J Clin Pract ; 64(13): 1802-7, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21070530

ABSTRACT

BACKGROUND: It is undecided whether glucose control as advocated by the professional organisations and the glucose-lowering method by itself affects clinical outcome in patients with diabetes mellitus hospitalised in general medical wards. Our aim was to investigate whether a basal/bolus regimen and a modified prehospitalisation regimen have a different impact on the clinical diabetic patients in general medicine wards. METHODS: Glucose control of patients with diabetes hospitalised in two different wards of internal medicine was achieved according to their wards' policy: a modified preadmission regimen (conventional regime) or a basal/bolus regimen (intensive regime). Death and any adverse event were determined during hospitalisation and within 6 months after discharge to assess clinical outcome. RESULTS: Median fasting and daily glucose levels were similar in the conventional (n = 116) and intensive regime (n = 129) groups: 161 mg/dl (inter-quartile range: 138-201) and 176 mg/dl (152-215) vs. 155 mg/dl (133-208) and 173 mg/dl (146-208) respectively. Clinical outcome was not affected by the treatment modality. In the subgroup of patients hospitalised with infection, the median fasting glucose was significantly lower in the interventional compared with the conventional regime: 141 and 172 mg/dl respectively (p = 0.041). However, tighter control was associated with a significantly higher incidence of adverse events within 6 months after discharge: 48.9% and 21.4% respectively (p = 0.047). CONCLUSION: In general medicine wards, modified prehospital hypoglycaemic regimens and a basal/bolus insulin regimen achieve similar glucose control. The clinical outcome was not affected by the modality of glucose control.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hospitalization/statistics & numerical data , Hypoglycemic Agents/administration & dosage , Adult , Aged , Aged, 80 and over , Blood Glucose/metabolism , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/mortality , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/mortality , Female , Glycated Hemoglobin/metabolism , Humans , Hypoglycemia/chemically induced , Hypoglycemic Agents/adverse effects , Male , Middle Aged , Treatment Outcome , Young Adult
5.
Nutr Metab Cardiovasc Dis ; 19(9): 641-5, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19201586

ABSTRACT

BACKGROUND AND AIM: Intracellular magnesium (icMg) depletion may coexist with normomagnesemia. Mg deficiency (serum and/or intracellular) and decreased heart rate variability (HRV) are common in heart failure (HF). Since both are predictors of poor prognosis, it was of interest to evaluate the effect of Mg supplementation on HRV in patients with HF. METHODS AND RESULTS: We investigated the effect of Mg administration on HRV in normomagnesemic patients with systolic HF. HRV, serum Mg and icMg were determined before and after 5-week 300 mg/day Mg citrate treatment in 16 patients (group 1). The control group included 16 Mg-non-treated HF patients (group 2). HRV was determined by a non-linear dynamics analysis, derived from the chaos theory, which calculates HRV-correlation dimension (HRV-CD). After 5 weeks, serum Mg (mmol/l) increased more significantly in group 1 (from 0.78+/-0.04 to 0.89+/-0.06, p<0.001), than in group 2 (from 0.79+/-0.07 to 0.84+/-0.06, p=0.042). IcMg and HRV-CD increased significantly only in group 1 (from 59+/-7 to 66+/-9 mmol/g cell protein, p=0.025, and from 3.47+/-0.42 to 3.94+/-0.36, p<0.001, respectively). In group 2, the differences in the respective parameters were 63+/-12 to 66+/-9 mmol/g cell protein (p=0.7) and 3.59+/-0.42 to 3.55+/-0.4 (p=0.8). CONCLUSION: Mg administration to normomagnesemic patients with systolic HF increases serum Mg, icMg and HRV-CD. Increasing of HRV by Mg supplementation may prove beneficial to HF patients.


Subject(s)
Heart Failure, Systolic/drug therapy , Heart Failure, Systolic/metabolism , Heart Rate/drug effects , Magnesium/administration & dosage , Magnesium/blood , Aged , Comorbidity , Cytosol/metabolism , Electrocardiography, Ambulatory , Female , Heart Failure, Systolic/epidemiology , Humans , Male , Middle Aged , Nonlinear Dynamics , Prognosis , Treatment Outcome
6.
Am J Physiol Lung Cell Mol Physiol ; 295(4): L552-65, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18658273

ABSTRACT

Nanomaterials are frontier technological products used in different manufactured goods. Because of their unique physicochemical, electrical, mechanical, and thermal properties, single-walled carbon nanotubes (SWCNT) are finding numerous applications in electronics, aerospace devices, computers, and chemical, polymer, and pharmaceutical industries. SWCNT are relatively recently discovered members of the carbon allotropes that are similar in structure to fullerenes and graphite. Previously, we (47) have reported that pharyngeal aspiration of purified SWCNT by C57BL/6 mice caused dose-dependent granulomatous pneumonia, oxidative stress, acute inflammatory/cytokine responses, fibrosis, and decrease in pulmonary function. To avoid potential artifactual effects due to instillation/agglomeration associated with SWCNT, we conducted inhalation exposures using stable and uniform SWCNT dispersions obtained by a newly developed aerosolization technique (2). The inhalation of nonpurified SWCNT (iron content of 17.7% by weight) at 5 mg/m(3), 5 h/day for 4 days was compared with pharyngeal aspiration of varying doses (5-20 microg per mouse) of the same SWCNT. The chain of pathological events in both exposure routes was realized through synergized interactions of early inflammatory response and oxidative stress culminating in the development of multifocal granulomatous pneumonia and interstitial fibrosis. SWCNT inhalation was more effective than aspiration in causing inflammatory response, oxidative stress, collagen deposition, and fibrosis as well as mutations of K-ras gene locus in the lung of C57BL/6 mice.


Subject(s)
Administration, Inhalation , Inflammation/etiology , Lung/drug effects , Mutagenesis , Nanotubes, Carbon/adverse effects , Oxidative Stress/drug effects , Respiration Disorders/chemically induced , Aerosols/administration & dosage , Animals , Carbon/pharmacology , Female , Fibrosis , Inflammation/pathology , Lung/pathology , Mice , Mice, Inbred C57BL , Pharynx
7.
Acta Diabetol ; 43(2): 46-51, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16865329

ABSTRACT

Drugs modulating the ATP-sensitive potassium (K(ATP)) channel activity are widely used for the treatment of diabetes mellitus, the target being pancreatic beta-cells. However, any cell type possessing K(ATP) channels might be concomitantly affected. We investigated the metabolic effect of glibenclamide, a K(ATP) channel closer, and/or diazoxide, a K(ATP) channel opener, on total intracellular content of calcium (Ca) and magnesium (Mg) of cultured peripheral blood mononuclear cells (PBMC). Metformin and rosiglitazone, acting via cellular mechanisms other than K(ATP) channels, were also tested. Ca and Mg were assessed in PBMC from healthy subjects following 72 h in vitro treatment with the respective drugs. Ca content increased significantly in PBMC treated with glibenclamide or rosiglitazone, however apparently via different intracellular pathways. Mg increased only following treatment with rosiglitazone. Metformin had no effect on intracellular Ca or Mg. Pretreatment with diazoxide resulted in a significant intracellular Ca and Mg loss in each experimental situation. If verified clinically, rosiglitazone-induced increase in Mg content of PBMC might prove beneficial beyond hypoglycaemic control. On the other hand, loss of intracellular Ca/Mg content following K(ATP) channel opening by diazoxide might eventually result in significant intracellular Ca and/or Mg depletion.


Subject(s)
Calcium/blood , Hypoglycemic Agents/pharmacology , Leukocytes/drug effects , Magnesium/blood , Adult , Cells, Cultured , Diazoxide/pharmacology , Glyburide/pharmacology , Humans , Metformin/pharmacology , Middle Aged , Potassium Channels/metabolism , Rosiglitazone , Thiazolidinediones/pharmacology
8.
Infection ; 32(3): 179-81, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15188080

ABSTRACT

We describe two splenectomized patients admitted with pneumonia. The course in one was complicated by overwhelming multiorgan failure when the only indicative laboratory result was seropositivity for Legionella hackeliae and Legionella longbeachae. He was initially treated with ceftriaxone and roxithromycin, followed by levofloxacin as well as intensive supportive treatment, and survived. The second patient was seroreactive for Legionella micdadei. In some cases of pneumonia in splenectomized patients tentatively considered to be caused by Streptococcus pneumoniae, the causative agent might have, in fact, been Legionella. We suggest that splenectomy be considered a possible predisposing factor for Legionella pneumonia. Since prompt diagnosis of Legionella infection, especially the non- pneumophila species, is extremely difficult, alertness to this diagnostic option and early empirical initiation of appropriate aggressive antibiotic treatment may be of critical importance.


Subject(s)
Antibodies, Bacterial/blood , Legionella longbeachae/immunology , Legionella/immunology , Legionnaires' Disease/epidemiology , Legionnaires' Disease/microbiology , Splenectomy/adverse effects , Adult , Causality , Community-Acquired Infections/epidemiology , Community-Acquired Infections/microbiology , Female , Humans , Male
9.
Clin Nephrol ; 61(3): 177-84, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15077868

ABSTRACT

AIMS: Many congestive heart failure (CHF) patients suffer from various comorbidities, which may aggravate CHF or independently increase mortality risk. Renal failure (RF) is one of them. We defined bedside clinical, laboratory and electrocardiographic parameters characterizing CHF patients with and without concomitant RF, and analyzed their impact on mortality. METHODS: We studied symptomatic unselected consecutive furosemide-treated CHF patients hospitalized for various acute conditions. On admission, history taking, physical examination, chest x-ray, ECG and routine laboratory tests were performed. Subsequently, patients were divided into 2 subgroups, those with serum creatinine > or = 1.5 mg/dl (RF) and those with lower values. Following discharge, information concerning mortality and circumstance of death was obtained from hospital records and outpatient death certificates. RESULTS: Included were 398 patients, 163 (40.9%) with RF and 235 free of RF. Prevailing in the RF subgroup were older age (mean age 75.5 vs 70.8, p < 0.001), male gender (p < 0.001), admission pulmonary edema (p = 0.007), cardiac arrhythmias (p = 0.05), cardiac conduction disturbances (p = 0.002), severe CHF (p = 0.005), lower ejection fraction (p = 0.03), anemia (p = 0.009), higher furosemide maintenance dosages (p < 0.001), insulin treatment (p = 0.03) and receiving less ACE inhibitors (p = 0.006). On median follow-up of 43 months, mortality was 54.9% in the RF vs 31.9% in the non-RF subgroup (p < 0.001), RF being the parameter most significantly associated with low survival (OR 1.97, p < 0.001). In the RF subgroup older age (p < 0.02), female gender (p < 0.003) and not using ACE inhibitors (p = 0.04) or drugs with antiarrhythmic effects (p < 0.005), emerged significantly associated with low survival, while diabetes mellitus (DM) and admission pulmonary edema tended to be so associated (p < 0.2). Using multivariate analysis in the RF subgroup, older age, female gender and DM proved most significantly associated with poorer survival (p = 0.004, OR 1.5, p = 0.03, OR 1.72, p = 0.04, OR 1.28, respectively). In the non-RF subgroup, only older age (p = 0.005) and DM (p = 0.05) were significantly associated with low survival. Sudden death occurred in 21 patients, 14 (8.6%) in the RF and 7 (3%) in the non-RF subgroup (p < 0.001). CONCLUSIONS: RF is a marker of severity in CHF. Its full-blown deleterious prognostic effect is already manifested at serum creatinine 1.5 mg/dl. Older age, DM and female gender most significantly heralded a shorter survival. Such patients require special care.


Subject(s)
Heart Failure/physiopathology , Renal Insufficiency/physiopathology , Aged , Case-Control Studies , Comorbidity , Diabetes Mellitus/epidemiology , Female , Heart Failure/complications , Heart Failure/mortality , Humans , Male , Multivariate Analysis , Prognosis , Proportional Hazards Models , Prospective Studies , Renal Insufficiency/complications , Renal Insufficiency/mortality , Risk Factors , Sex Factors , Survival Analysis
10.
Heart ; 89(4): 411-6, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12639869

ABSTRACT

OBJECTIVES: To determine the prevalence of hypomagnesaemia and hypermagnesaemia, to discern various factors associated with abnormal serum magnesium, and to estimate prognostic significance of serum magnesium aberrations in patients with congestive heart failure. DESIGN: Observational study. SETTING: Medical department of a university hospital (tertiary referral centre). PATIENTS: 404 consecutive patients admitted with congestive heart failure as one of the diagnoses and previously treated with furosemide (frusemide) for at least three months. MAIN OUTCOME MEASURES: Clinical, biochemical, and electrocardiographic variables were analysed with respect to serum magnesium aberrations. Following discharge, mortality rates, including sudden death, were registered. RESULTS: Hypomagnesaemia was found in 50 patients (12.3%) and 20 (4.9%) were hypermagnesaemic. Female sex (p < 0.04), diabetes mellitus (p < 0.006), hypocalcaemia (p = 0.03), hyponatraemia (p < 0.05), malignant disease (p = 0.05), and high fever (p = 0.05) were statistically associated with hypomagnesaemia. Renal failure, severe congestive heart failure, and high dose furosemide treatment (> 80 mg/day) were associated with hypermagnesaemia (p < 0.001, p = 0.05, and p < 0.03, respectively). Hypermagnesaemic patients were older and weighed less. On follow up (median duration 43 months), 169 (41.8%) died, with 22 (13%) sudden deaths. Mortality was highest with hypermagnesaemia, lowest with normomagnesaemia, and intermediate with hypomagnesaemia. After adjustment for renal failure, old age, and severity of congestive heart failure, hypomagnesaemia but not hypermagnesaemia emerged as being significantly associated with shorter survival (p = 0.009). No statistical association was found between sudden death and magnesium concentrations. CONCLUSIONS: While hypermagnesaemia seems to represent a prognostic marker only, hypomagnesaemia appears to have an adverse pathophysiological effect. The subgroup of patients at risk for hypomagnesaemia requires frequent serum magnesium determinations and magnesium replacement for as long as hypomagnesaemia persists.


Subject(s)
Diuretics/therapeutic use , Furosemide/therapeutic use , Heart Failure/drug therapy , Magnesium Deficiency/complications , Magnesium/blood , Aged , Female , Heart Failure/blood , Heart Failure/mortality , Humans , Magnesium Deficiency/blood , Male , Prognosis , Risk Factors , Survival Analysis
11.
Rheumatol Int ; 20(4): 163-6, 2001 May.
Article in English | MEDLINE | ID: mdl-11411962

ABSTRACT

Acute inflammatory myopathy with severe subcutaneous edema is extremely rare and has been reported in only a handful of cases. We describe two similar patients presenting with this disorder and generalized rash. Unlike the five previously reported cases, the clinical and histologic features of our two patients are more suggestive of dermatomyositis than polymyositis. Nevertheless, scrutinizing all seven reported patients, a number of specific characteristics could be defined. All patients were adult males. Dysphagia was present in four. In six patients, acute inflammatory myopathy was idiopathic while malignancy was present in one. Two patients died despite intensive therapy, three improved on corticosteroid treatment, and two recovered spontaneously. In all patients, limb involvement with marked subcutaneous edema was present, clinically mimicking deep vein thrombosis in both our patients. The presence of severe subcutaneous edema may be a hallmark of a distinctive variant of acute inflammatory myopathy. More cases are needed to discern subtypes of this general entity and to establish guidelines for treatment and prognosis.


Subject(s)
Edema/complications , Myositis/complications , Skin Diseases/complications , Acute Disease , Adrenal Cortex Hormones/therapeutic use , Adult , Edema/diagnosis , Follow-Up Studies , Humans , Male , Middle Aged , Myositis/diagnosis , Myositis/drug therapy , Severity of Illness Index , Skin Diseases/diagnosis , Treatment Outcome
12.
Clin Cardiol ; 24(5): 380-4, 2001 May.
Article in English | MEDLINE | ID: mdl-11346246

ABSTRACT

BACKGROUND: Despite reported evidence of the vital importance of appropriate anticoagulation in patients with chronic atrial fibrillation for stroke prevention, this treatment modality still lags behind optimal requirements. HYPOTHESIS: Our objectives were to evaluate various doctor or patient-related factors that influence quality of control and to assess the adequacy of anticoagulation provided by physicians in the community. METHODS: In a retrospective study, International Normalized Ratio (INR) values obtained immediately on admission to hospital were considered representative of previous long-term control. RESULTS: Only 42% of the relevant 385 patient population fell within the protective anticoagulation range of INR 1.91-4.1. The respective figures for patients with poor (INR < 1.5) or suboptimal (INR 1.51-1.9) control, as well as those whose INR values risked bleeding (INR > 4.1), were 28.3, 14.1, and 15.6%. Patient involvement in treatment positively influenced quality of control. By contrast, age 70-80 years or absence of congestive heart failure negatively affected quality of anticoagulation [p = 0.07, odds ratio (OR), 1.7 (95% confidence interval. 0.94-3.08), p = 0.014, OR, 2.06 (95% confidence interval, 1.15-3.7) respectively]. The percentage of patients admitted with stroke who had been adequately anticoagulated was significantly lower than that of patients who had no stroke (21 vs. 44.4%). Adequacy of anticoagulation in patients with cardiac prosthetic valves was superior compared with the rest of the patient population (56.7 vs. 42% with optimal, and only 14.5 vs. 28.3% with poor anticoagulation, respectively), indicating that under the same conditions a better quality of treatment could be achieved. CONCLUSIONS: Adequacy of anticoagulation in patients with atrial fibrillation lags behind actual recommendations. Better control is required and achievable.


Subject(s)
Atrial Fibrillation/complications , International Normalized Ratio , Stroke/prevention & control , Aged , Aged, 80 and over , Female , Guideline Adherence , Heart Valve Prosthesis , Humans , Male , Multivariate Analysis , Quality of Health Care , Retrospective Studies , Stroke/complications , Treatment Outcome
13.
J Infect ; 41(3): 277-82, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11120621

ABSTRACT

We describe two patients with acute leukaemia who died of massive haemoptysis caused by invasive pulmonary aspergillosis (IPA). The fatal event occurred during the period of bone marrow remission which followed chemotherapy-induced neutropenia. This is a rare complication. We were able to find additional 17 similar cases in the English literature, which we review. Clinically, the picture consisted of unremitting fever with profound and prolonged neutropenia, cough and dyspnoea. Both our patients were treated with broad-spectrum antibiotics, fluconazole and amphotericin B. An upper lobe infiltrate in one case, and a progressive pleural effusion in the other, were late findings on chest radiographs during the period of bone marrow recovery. Both patients succumbed to sudden massive haemoptysis during the period of bone marrow and clinical improvement. In conclusion, patients with acute non-lymphoid leukaemia are at significant risk for IPA-induced fatal haemoptysis during bone marrow and clinical remission. A high index of suspicion should be sustained throughout the entire clinical course. In view of the potential fatal outcome, aggressive diagnostic and treatment efforts are mandatory.


Subject(s)
Aspergillosis/complications , Hemoptysis/etiology , Leukemia, Myeloid/drug therapy , Lung Diseases, Fungal/complications , Acute Disease , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fatal Outcome , Female , Humans , Leukemia, Myeloid/complications , Middle Aged , Remission Induction
14.
Stroke ; 31(6): 1217-22, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10835435

ABSTRACT

BACKGROUND AND PURPOSE: The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established. However, the prevalence of such treatment generally lags behind actual requirements. The aim of this study was to evaluate doctor- and/or patient-related demographic, clinical, and echocardiographic factors that influence decision for warfarin treatment. METHODS: Between 1990 and 1998, 1027 patients were discharged with chronic or persistent atrial fibrillation. This population was composed of (1) patients with cardiac prosthetic valves (n=48), (2) those with increased bleeding risks (n=152), (3) physically or mentally handicapped patients (n=317), and (4) the remaining 510 patients, the main study group who were subjected to thorough statistical analysis for determining factors influencing warfarin use. RESULTS: The respective rates of warfarin use on discharge in the 4 groups were 93.7%, 30.9%, 17.03%, and 59.4% (P=0.001); of the latter, an additional 28.7% were discharged on aspirin. In the main study group, warfarin treatment rates increased with each consecutive triennial period (29.7%, 53.6%, and 77.1%, respectively; P=0.001). Age >80 years, poor command of Hebrew, and being hospitalized in a given medical department emerged as independent variables negatively influencing warfarin use: P=0.0001, OR 0.30 (95% CI 0.17 to 0.55); P=0.02, OR 0.59 (95% CI 0.36 to 0.94); and P=0.0002, OR 0.26 (95% CI 0.12 to 0.52), respectively. In contrast, past history of stroke and availability of echocardiographic information, regardless of the findings, each increased warfarin use (P=0.03, OR 1.95 [95% CI 1.04 to 3.68], and P=0.0001, OR 3.52 [95% CI 2.16 to 5.72], respectively). CONCLUSIONS: Old age, language difficulties, insufficient doctor alertness to warfarin benefit, and patient disability produced reluctance to treat. Warfarin use still lags behind requirements.


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Practice Patterns, Physicians' , Stroke/prevention & control , Warfarin/therapeutic use , Age Factors , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Aspirin/administration & dosage , Aspirin/therapeutic use , Atrial Fibrillation/complications , Atrial Fibrillation/diagnostic imaging , Atrial Fibrillation/epidemiology , Chronic Disease , Communication Barriers , Comorbidity , Drug Prescriptions/statistics & numerical data , Drug Utilization , Echocardiography , Female , Heart Diseases/complications , Heart Diseases/diagnostic imaging , Heart Diseases/epidemiology , Hospital Departments , Hospitalization , Humans , Israel , Lung Diseases, Obstructive/epidemiology , Male , Middle Aged , Physician-Patient Relations , Physicians/psychology , Recurrence , Refusal to Treat , Retrospective Studies , Risk Factors , Stroke/etiology , Thyrotoxicosis/epidemiology , Warfarin/administration & dosage
15.
Clin Cardiol ; 23(6): 433-6, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10875034

ABSTRACT

BACKGROUND: Magnesium depletion and hypomagnesemia are common among furosemide-treated patients with chronic congestive heart failure. HYPOTHESIS: This investigation evaluated clinical and metabolic effects of oral magnesium supplementation. METHODS: Ten patients with severe congestive heart failure maintained on high dose furosemide (> or = 80 mg/day) received a supplement of oral magnesium citrate 300 mg/daily for 30 days. Clinical parameters were followed, and peripheral blood mononuclear cell magnesium and zinc content, serum and urine magnesium, potassium, zinc, calcium, phosphorus, and creatinine were assessed. RESULTS: Peripheral blood mononuclear cell magnesium content and serum potassium rose significantly at the end of the study (2.09 +/- 1.89 to 3.99 +/- 2.26 micrograms/mg cell protein, p < 0.05, and 4.17 +/- 0.38 to 4.39 +/- 0.27 mEq/l, p < 0.05, respectively), while the other parameters remained unchanged. CONCLUSION: In some of these patients, oral magnesium supplementation is effective in achieving substantial increments in intracellular magnesium and serum potassium which, in turn, may have cardioprotective effects.


Subject(s)
Citric Acid/pharmacology , Dietary Supplements , Diuretics/therapeutic use , Furosemide/therapeutic use , Heart Failure/drug therapy , Organometallic Compounds/pharmacology , Administration, Oral , Adult , Aged , Cardiomyopathy, Dilated/complications , Citric Acid/administration & dosage , Female , Heart Failure/etiology , Heart Failure/metabolism , Humans , Male , Middle Aged , Myocardial Ischemia/complications , Organometallic Compounds/administration & dosage
16.
J Clin Gastroenterol ; 29(1): 59-62, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10405234

ABSTRACT

Metoclopramide, a benzamide substitute, is used frequently as an antiemetic drug. Sulpiride, another benzamide substitute, was investigated and found to be safe and effective in a handful of studies involving only oncologic or other severely symptomatic patients. In this investigation the authors compared prospectively the antiemetic efficacy of sulpiride versus metoclopramide in a double-blind, randomized study involving 36 nononcologic patients with transient vomiting or nausea of various etiologies. Each group of 18 patients received oral metoclopramide or sulpiride (10 mg or 50 mg respectively) every 8 hours for a total of three doses each (24 hours of treatment). A 5-point score was used to evaluate symptomatic relief. Efficacy of the two drugs proved similar, and at the end of the study, 14 and 13 of 18 patients on sulpiride or metoclopramide respectively were asymptomatic. Only transient, minor side effects were reported in one patient in each group. The authors conclude that sulpiride is an effective and safe antiemetic drug that can be adopted legitimately in such cases as a first choice, or serve as an equipotent alternative to metoclopramide in patients sensitive to the latter.


Subject(s)
Antiemetics/therapeutic use , Metoclopramide/therapeutic use , Nausea/drug therapy , Sulpiride/therapeutic use , Vomiting/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antiemetics/administration & dosage , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Metoclopramide/administration & dosage , Middle Aged , Prospective Studies , Sulpiride/administration & dosage , Treatment Outcome
17.
Klin Khir (1962) ; (4): 26-8, 1991.
Article in Russian | MEDLINE | ID: mdl-1881071

ABSTRACT

The results of treatment of 41 patient with diffuse purulent peritonitis, who underwent 2 and more relaparotomies are analysed. It has been proved that performance of the elective relaparotomy for preventing the development of intraabdominal complications of peritonitis were superior to the existing methods of treatment. It permitted to reduce lethality in diffuse purulent peritonitis 3.6-fold.


Subject(s)
Abscess/surgery , Drainage/methods , Peritonitis/surgery , Surgical Wound Infection/surgery , Abscess/etiology , Abscess/prevention & control , Adolescent , Adult , Female , Humans , Intraoperative Care , Male , Middle Aged , Peritoneal Lavage , Peritonitis/complications , Reoperation/methods , Surgical Wound Infection/etiology , Surgical Wound Infection/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...